様々な種類の大麻の健康への影響に関する過去最大の研究により、より強力な大麻に対する懸念が浮き彫りになりました。 Largest ever study into the health effects of different types of cannabis highlights concerns about stronger forms of the drug.
2022-07-25 バース大学
The new systematic review from Kat Petrilli and Tom Freeman (Psychology) is published in The Lancet Psychiatry. Image credit: AdobeStock.
Lancet Psychiatry誌に掲載された今回の研究では、高活性の大麻を使用する人は、低活性の製品を使用する人よりも中毒になる可能性が高いことが示唆されています。また、高活性の大麻を使用している人は、統合失調症などの精神病性障害を経験する可能性が高いことも示唆されています。
これらの知見は、近年、大麻の問題で治療を受ける人が増えている理由を説明するのに役立つと考えられます。欧州薬物・薬物中毒監視センターのデータによると、過去10年間に大麻中毒の治療を受ける人が76%増加したことが示されています。
<関連情報>
- https://www.bath.ac.uk/announcements/high-strength-cannabis-linked-to-addiction-and-mental-health-problems/
- https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(22)00161-4/fulltext
大麻の効力と精神疾患および依存症との関連性:システマティックレビュー Association of cannabis potency with mental ill health and addiction: a systematic review
Kat Petrilli, Shelan Ofori, Lindsey Hines, Gemma Taylor, Sally Adams, Tom P Freeman
Lancet Psychiatry Published:July 25, 2022
DOI:https://doi.org/10.1016/S2215-0366(22)00161-4
Summary
Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from database inception to Jan 14, 2021). Included studies were observational studies of human participants comparing the association of high-potency cannabis (products with a higher concentration of THC) and low-potency cannabis (products with a lower concentration of THC), as defined by the studies included, with depression, anxiety, psychosis, or cannabis use disorder (CUD). Of 4171 articles screened, 20 met the eligibility criteria: eight studies focused on psychosis, eight on anxiety, seven on depression, and six on CUD. Overall, use of higher potency cannabis, relative to lower potency cannabis, was associated with an increased risk of psychosis and CUD. Evidence varied for depression and anxiety. The association of cannabis potency with CUD and psychosis highlights its relevance in health-care settings, and for public health guidelines and policies on cannabis sales. Standardisation of exposure measures and longitudinal designs are needed to strengthen the evidence of this association.
